Skip to Main Content

Paper Details

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Clin Cancer Res
16
2022
Bevacizumab, CD8, CD8+Ki67+ T cells, Circulating Immune, Circulating Immune Cell, Dexamethasone, Glioblastoma, Ki67, Ki67+ T cells, Ki67+CD8+ cells, MGMT, PD-L1, Patients, bevacizumab, circulating immune cell, circulating immune cell subsets, circulating immune cells, dexamethasone, durvalumab, effector immune cell subsets, glioblastoma, immune cell subsets, patients, recurrent glioblastoma, tumor
Author NameAffiliation
Timothy F CloughesyUniversity of California los angeles
Timothy F CloughesyUniversity of California los angeles
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute
Raymond Y HuangBrigham and Women's Hospital
Thomas J KaleyMemorial Sloan Kettering Cancer Center
  • 1 - 5

Datasets

Release 1.2